Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer
Merck is making a $125 million investment in Moderna as part of a new funding round. " We ' re encouraged by the potential for RNA-based vaccines, " says Eric Rubin, a Merck vice president.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:MRK NASDAQ:ABUS Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Funding | Merck | Pharmaceuticals | Vaccines